Figure 2.

Recombinant fetuin B aggravated hepatic lipid accumulation in HepG2 cells. Hepatocellular lipid accumulation and AMPK-/LXR-pathways were evaluated after the administration of recombinant fetuin B in HepG2 cells exposed to FFAs. A: Oil Red O staining: FFA vs. FFA + Rec FetB (200 × and 400 ×); B: Intercellular TG content (FFA vs. FFA + Rec FetB, P = 0.001); C: The expression of key proteins in the AMPK and LXR pathways; D: The mRNA levels of lipid metabolic enzymes; Rec FetB, Recombinant fetuin B. Results are the mean ± SD of three independent experiments, each repeated in triplicate.